Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, Proof-of-concept trial of KER-047 in patients with iron-refractory, iron deficiency anemia and other anemias with elevated hepcidin, including myelofibrosis.

Next Previous
Trial Profile

A phase II, Proof-of-concept trial of KER-047 in patients with iron-refractory, iron deficiency anemia and other anemias with elevated hepcidin, including myelofibrosis.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KER 047 (Primary)
  • Indications Anaemia; Iron deficiency anaemia; Myelofibrosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Keros Therapeutics

Most Recent Events

  • 09 Mar 2022 According to a Keros Therapeutics media release, the company expects to initiate this trial in the first half of 2022 and report initial data from both trials by the end of 2022
  • 04 Aug 2020 According to a Keros Therapeutics media release, expect commencement of this trial in first half of 2021.
  • 11 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top